SEC Comment Letter 0000000000-24-011838 to Shepherd Ave Capital Acquisition Corp (SPHA, SPHAU) (CIK 0002030829) (PGAC)
Shepherd Ave Capital Acquisition Corp (SPHA, SPHAU) (CIK 0002030829)
Date: Oct. 23, 2024 · CIK: 0002030829 · Accession: 0000000000-24-011838
AI Filing Summary & Sentiment
File numbers found in text: 333-280986
Show Raw Text
October 23, 2024
William W. Snyder
Chief Executive Officer and Chairman
Shepherd Ave Capital Acquisition Corp
221 W 9th St, #859
Wilmington, DE 19801
Re:Shepherd Ave Capital Acquisition Corp
Amendment No. 1 to
Registration Statement on Form S-1
Filed October 3, 2024
File No. 333-280986
Dear William W. Snyder:
We have reviewed your amended registration statement and have the following
comments.
Please respond to this letter by amending your registration statement and providing
the requested information. If you do not believe a comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information
you provide in response to this letter, we may have additional comments. Unless we note
otherwise, any references to prior comments are to comments in our September 23, 2024
letter.
Amendment No. 1 to Form S-1 filed October 3, 2024
Cover page
1.We note your revised disclosure in response to prior comment 1. Please further revise
your dilution table, here and on pages 15 and 85, to present dilution at quartile
intervals based on percentages of your maximum redemption threshold. Refer to Item
1602(a)(4) of Regulation S-K.
2.Please tell us why you are presenting possible sources of dilution as the lead-in to
your tabular presentation rather than providing effect to material probable or
consummated transactions as prescribed in Rule 1602(a)(4) of Regulation S-K. This
comment also applies to your presentations on pages 14 and 85.
October 23, 2024
Page 2
3.Refer to prior comment 3. Please also provide cross references on the cover page to
the sponsor compensation disclosure in the summary on page 5 and the conflicts of
interest disclosure on page 31.
4.We note your response to prior comment 6; however, we do not see revised disclosure
in response to that comment. Please disclose the price per share for the Class B
ordinary shares paid by the sponsor on the cover page. See Regulation S-K Item
1602(a)(3). For clarity, please separately disclose the price paid for each issuance of
securities to the sponsor, its affiliates, and promoters.
Summary, page 1
5.Please refer to prior comment 10. We note your disclosure that if you increase or
decrease the size of this offering, you will effect a share capitalization or a
compulsory redemption or redemption or other appropriate mechanism, as applicable.
Please disclose the antidilution adjustment of the insider shares, the payment of
consulting, management or other fees that may be received by directors or members of
your management team as disclosed on page 121, the monthly compensation
payments to be made to your Chief Executive Officer and Chief Financial Officer and
the amount of Class B securities issued to them. Lastly, describe the extent to which
these items of compensation and/or securities issuances may result in a material
dilution of the purchasers’ equity interests.
6.Please expand your disclosure in response to prior comment 12 to address
additional consequences to the sponsor and its affiliates of not completing an
extension including the effect on repayment of any outstanding working capital loans,
out of pocket expenses and amounts due as compensation to the officers of the
company.
Conflicts of interest, page 31
7.We note your revised disclosure in response to prior comment 11 and reissue that
comment in part. We note that your sponsor, officers and directors, may receive
certain reimbursement or repayment of loans that may be dependent on the closing of
our initial business combination. Please describe clearly the conflict of interest
regarding such out of pocket expenses or loans, including, if true, that your sponsor,
officers and directors may not receive repayment of such amounts in the event that
that a business combination does not proceed and could lose such amounts, and
therefore have an interest in ensuring that a business combination does proceed to
ensure repayment. Disclose the potential conflicts of interest arising from the ability
to pursue a business combination with a company that is affiliated with the Sponsor or
members of your management team. Please also revise the section beginning on page
123 to address these conflicts.
Dilution, page 83
8.We reissue prior comment 16 in part. Please highlight that you may need to issue
additional securities as you intend to seek an initial business combination with a target
company with an enterprise value greater than the net proceeds of the offering and the
sale of private placement warrants.
October 23, 2024
Page 3
Conflicts of Interest, page 123
9.Refer to prior comment 17. We note your revised disclosure that if any of your
officers or directors becomes aware of a business combination opportunity which is
suitable for an entity to which he or she has then-current fiduciary or contractual
obligations, he or she will honor his or her fiduciary or contractual obligations to
present such business combination opportunity to such entity and that you renounce
any interest or expectancy in, or in being offered an opportunity to participate in, any
potential transaction or matter which may be a corporate opportunity for any director
or officer. Given this disclosure, please explain the basis for your conclusions that you
not believe that waiver of the corporate opportunities doctrine will create any conflicts
of interest, affect your search for an acquisition target, or materially affect your ability
to complete a business combination, and that you do not believe that the fiduciary
duties or contractual obligations of your officers or directors will materially affect
your ability to complete your initial business combination.
Please contact Kellie Kim at 202-551-3129 or Isaac Esquivel at 202-551-3395 if you
have questions regarding comments on the financial statements and related matters. Please
contact Ruairi Regan at 202-551-3269 or Mary Beth Breslin at 202-551-3625 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Real Estate & Construction
cc:Arila E. Zhou, Esq.